Krishna Institute of Medical Sciences is pushing deeper into India’s fast-growing tier-2 healthcare market with a major expansion in Amaravati, reflecting the broader industry trend of hospital chains moving beyond metro cities to tap underserved regions.
The hospital chain’s shares jumped 8.40% on May 11, 2026, ending at ₹777.85 after the company announced plans for a 500-bed multi-speciality hospital in Amaravati. The project will come up on land leased for 60 years from the Andhra Pradesh Capital Region Development Authority.
The proposed facility is expected to strengthen access to advanced healthcare services across Andhra Pradesh and nearby districts, reducing the dependence on metropolitan hospitals for specialized treatment.
Investor sentiment also remained positive, with foreign institutional investor holdings inching up to 14.57% in the March 2026 quarter from 14.33% in December 2025.
KIMS’ Amaravati investment mirrors a wider shift in India’s healthcare landscape, where smaller cities are increasingly becoming growth hotspots. Rising incomes, urbanization, and stronger healthcare awareness are driving demand for quality medical services in these regions, even as infrastructure gaps remain.
With Andhra Pradesh actively improving healthcare infrastructure through policy support and investments, the environment appears favorable for large private hospital operators seeking long-term expansion opportunities.
Despite strong expansion momentum, KIMS continues to face concerns over its valuation. The company currently commands a market capitalization of nearly ₹29,000 crore, while its trailing twelve-month price-to-earnings ratio has stayed above 90 and touched levels near 105 — substantially higher than the sector average of around 43.5.
This premium valuation has prompted some market observers to describe the stock as overvalued compared with peers such as Aster DM Healthcare and Fortis Healthcare.
Although revenue growth has remained healthy, profitability has come under pressure due to losses from newly launched hospitals in Maharashtra, Kerala, and Karnataka. Network occupancy has hovered around 50–54%, even as Average Revenue Per Occupied Bed (ARPOB) improved.
A majority of analysts continue to maintain a “Strong Buy” outlook, with 12-month target prices ranging between ₹760 and ₹804, reflecting confidence in the company’s long-term expansion strategy.
However, one assessment released on April 6, 2026, downgraded the stock to “Strong Sell,” citing weak technical indicators and underwhelming financial performance. The contrasting views underline uncertainty around whether future earnings can justify current valuations.
Expansion into tier-2 markets may offer growth opportunities, but competition remains intense. Major healthcare players including Apollo Hospitals, Max Healthcare, and Fortis are also strengthening their regional presence.
Execution risks are another concern. Previous KIMS projects, including facilities in Bengaluru, reportedly experienced significant cost escalations after revisions to original development plans. New hospitals typically require 9–12 months to achieve break-even, which may pressure margins in the short term.
While KIMS is gradually expanding into multiple states, a substantial portion of its business still remains concentrated in Telangana and Andhra Pradesh.
The company plans to add nearly 1,700 beds by FY27, backed by capital expenditure estimated at ₹13–15 billion.
While many analysts remain optimistic about KIMS’ long-term growth prospects and its expansion into underserved markets, concerns surrounding valuation, debt levels, execution capability, and regulatory scrutiny continue to keep investor opinion divided.
(Photo courtesy: www.kimshospitals.com)